Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GPR3 | P46089 | 1/20 | 0.33 |
| ▸ | GRN | P28799 | 1/20 | 0.32 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8812896 | 0.88 | CYP1A2 (0.38) | CYP1A2TSHRKMT2AGPR3POLB | |
| SCHEMBL30510335 | 0.88 | CYP1A2 (0.38) | CYP1A2TSHRKMT2AGPR3POLB | |
| SCHEMBL19899311 | 0.84 | CYP1A2 (0.32) | CYP1A2TSHRCTRB1KMT2AGPR3 | |
| SCHEMBL7107498 | 0.84 | PTPRC (0.36) | CYP1A2TSHRKMT2APOLBIDO1 | |
| SCHEMBL30510259 | 0.84 | CYP1A2 (0.38) | CYP1A2TSHRKMT2AGPR3POLB | |
| SCHEMBL1405873 | 0.84 | CYP1A2 (0.38) | CYP1A2TSHRKMT2AGPR3POLB | |
| SCHEMBL4599750 | 0.84 | CYP1A2 (0.38) | CYP1A2TSHRKMT2AGPR3POLB | |
| SCHEMBL1405820 | 0.84 | CYP1A2 (0.38) | CYP1A2TSHRKMT2AGPR3POLB | |
| SCHEMBL418100 | 0.83 | CYP1A2 (0.38) | CYP1A2TSHRKMT2AGPR3POLB | |
| SCHEMBL5497625 | 0.83 | CYP1A2 (0.47) | CYP1A2TSHRKMT2AGPR3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197378-A1 | SMALL MOLECULE MODULATORS OF IL-17 | LEO PHARMA AS (DK) | 2025-06-19 | — | — | US | disclosed |
| US-20220411461-A1 | METHODS OF MAKING INCRETIN ANALOGS | ELI LILLY AND COMPANY | 2022-12-29 | — | — | US | disclosed |
| EP-4017866-A1 | METHODS OF MAKING INCRETIN ANALOGS | Eli Lilly and Company (US) | 2022-06-29 | — | — | EP | disclosed |
| WO-2021034815-A1 | METHODS OF MAKING INCRETIN ANALOGS | ELI LILLY AND COMPANY (US) | 2021-02-25 | — | — | WO | disclosed |
| EP-2038295-B1 | PSEUDO PROLINE DIPEPTIDES | HOFFMANN LA ROCHE (CH) | 2011-02-09 | — | — | EP | disclosed |
| US-7612209-B2 | Pseudo proline dipeptides | HOFFMANN-LA ROCHE INC. (US) | 2009-11-03 | — | — | US | disclosed |
| EP-1515972-B1 | AMIDE SUBSTITUTED XANTHINE DERIVATIVES WITH GLUCONEOGENESIS MODULATING ACTIVITY | HOFFMANN LA ROCHE (CH) | 2009-05-13 | — | — | EP | disclosed |
| EP-2038295-A1 | PSEUDO PROLINE DIPEPTIDES | F.HOFFMANN-LA ROCHE AG (CH) | 2009-03-25 | — | — | EP | disclosed |
| US-20080004451-A1 | Pseudo proline dipeptides | HOFFMANN-LA ROCHE INC. | 2008-01-03 | — | — | US | disclosed |
| WO-2008000641-A1 | PSEUDO PROLINE DIPEPTIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-01-03 | — | — | WO | disclosed |
| US-7135475-B2 | Antidiabetic agents | HOFFMANN-LA ROCHE INC. (US) | 2006-11-14 | — | — | US | disclosed |
| EP-1515972-A1 | AMIDE SUBSTITUTED XANTHINE DERIVATIVES WITH GLUCONEOGENESIS MODULATING ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-23 | — | — | EP | disclosed |
| US-20040014766-A1 | Amide substituted xanthine derivatives | HOFFMANN-LA ROCHE INC. | 2004-01-22 | — | — | US | disclosed |
| WO-2003106459-A1 | AMIDE SUBSTITUTED XANTHINE DERIVATIVES WITH GLUCONEOGENESIS MODULATING ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014766-A1 | Amide substituted xanthine derivatives | GYS2, GLS2, PYGL | KEAP1 1768/4885CYP1A2 143/4885TSHR 1344/4885 |
| US-20250197378-A1 | SMALL MOLECULE MODULATORS OF IL-17 | IL17A, IL2, IL23R | KEAP1 1143/4885CYP1A2 724/4885TSHR 4178/4885 |
| US-20080004451-A1 | Pseudo proline dipeptides | PNISR, PTMS, ARGLU1 | KEAP1 3495/4885CYP1A2 3924/4885TSHR 284/4885 |
| US-20220411461-A1 | METHODS OF MAKING INCRETIN ANALOGS | IAPP, GLP1R, GIPR | KEAP1 1554/4885CYP1A2 4217/4885TSHR 1880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.